Injecting interest

Generic injectables seems to have become one of the hottest spaces in pharma. The latest to announce that it is eyeing deals in generic injectables is Dr Reddy’s. The Indian pharma wants to build its portfolio in more complex products like injectables, where shortages are frequent, competition is less intense and prices are higher.

Dr Reddy’s says it plans to seek FDA approval for 4 or 5 complex injectables in the next 24 to 30 months. The company’s intention is to build its percentage of US sales from complex products from 25% to 60% within the next 3 years. Planned complex products (known also as New Drug Delivery System generics) on its list include transdermal, topical and opthamological formulations as well as reformulated generic injectables.

Dr Reddy’s joins a growing list of companies with injectable drug ambitions:

• Mylan bought Strides Arcolabs injectables unit Agila Specialties in March 2013 for $1.6 billion.
• Par Pharmaceutical acquired injectables specialist JHP Pharmaceuticals in January 2014 for $490 million.
• India's Lupin acquired Netherlands-based drug delivery company Nanomi in February 2014 so that it could expand into complex injectables.
• Hikma paid up to $300 million to acquire the US generic injectables business of Boehringer Ingelheim in May 2014.
• Pfizer acquired injectables specialist pharma InnoPharma, in a deal worth up to $360 million in July 2014.
• Pfizer then stepped up its game when it acquired injectables specialist Hospira for $15 billion last month.

I wonder how the Mylan TPM/Antibiotic Lyophilized Powder for IV Injection in Complicated skin and skin structure infections is going? And then there’s POH’s unpartnered TPM/Propofol Injectable Emulsion.

I know that the company’s current main focus is the TPM Oxy patches, but in my opinion they would be mad not to be actively promoting their TPM injectable formulation capabilities while this market is hot.

http://www.fiercepharma.com/story/dr-reddys-shopping-deals-1b-it-expands- injectable-meds/2015-03-26

http://www.firstwordpharma.com/node/1271811?tsid=28&region_id=2#axzz3VZ7clefy